ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteoarthritis and Bone Disorders

Racial Disparities in Rheumatology: RA, OA & Arthroplasty

Thomas R. Collins  |  November 13, 2020

ACR CONVERGENCE 2020—Evidence shows that African Americans have a higher burden of osteoarthritis, with lower use of conventional medications, and are less adherent to the medications they take. They also get arthroplasty procedures less often, and when they do have the procedures, they report greater pain, worse function and lower satisfaction with them. In RA…

New Findings on Hydroxychloroquine, Denosumab

Ruth Jessen Hickman, MD  |  November 12, 2020

ACR Convergence 2020—At two plenary sessions, speakers highlighted key findings, including results on the QTc interval in patients on hydroxychloroquine, and data from a study on denosumab vs. alendronate for glucocorticoid-induced osteoporosis. The QTc Interval & Hydroxychloroquine The safety profile and optimal dosing of hydroxychloroquine has been a topic for decades because it is known…

Ticagrelor Lowers the Risk for OA Compared with Clopidogrel

Arthritis & Rheumatology  |  October 28, 2020

Preclinical models have provided important insights into the pathogenesis of OA and potential pathways for therapeutic intervention, including adenosine. Ticagrelor and clopidogrel are both used in patients with coronary artery disease, but only ticagrelor increases extracellular adenosine levels. In this study, treatment with ticagrelor was associated with a 29% lower risk of developing OA than treatment with clopidogrel over five years of follow-up.

Hand Pain Depends on More Than Osteoarthritis Severity & Psych Profile

Thomas R. Collins  |  October 19, 2020

Pain is the main reason patients with osteoarthritis (OA) seek medical help because of the substantial burden it imposes and its impact on quality of life. Pain can actually change the way the central nervous system works. This central sensitization results in more pain with less provocation. And according to results from an observational study…

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Ruth Jessen Hickman, MD  |  October 1, 2020

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

Arthroscopic Partial Meniscectomy Tied to Radiographic Knee OA

By Lisa Rapaport  |  September 29, 2020

(Reuters Health)—Patients with a degenerative meniscus tear who get arthroscopic partial meniscectomy have similar five-year outcomes and increased risk of radiographic knee osteoarthritis (OA) as without surgery, a small study suggests. Researchers in Finland randomly assigned 146 adults with degenerative meniscus tear confirmed by magnetic resonance imaging (MRI) to receive either arthroscopic partial meniscectomy (APM)…

Sedentary Lifestyle Linked to Reduced Quality of Life in People with Knee OA

Mary Beth Nierengarten  |  September 21, 2020

Physical inactivity significantly affects disease burden and reduces the overall quality of life in patients with knee osteoarthritis (OA), according to a study from Losina et al. The researchers calculated the total quality-adjusted life-years lost for U.S. patients with OA due to inactivity.

Bisphosphonates Reduce Bone Toughness Over Time

Will Boggs, MD  |  August 11, 2020

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B….

Abaloparatide vs. Alendronate for Osteoporosis

Lara C. Pullen, PhD  |  August 10, 2020

In a clinical trial, researchers compared the efficacy of abaloparatide with alendronate in reducing the risk of fracture among postmenopausal women with osteoporosis. The findings suggest initial treatment with abaloparatide may result in greater vertebral fracture reduction than alendronate…

IL-1-Beta Blockade May Slow OA Progression

Reuters Staff  |  August 4, 2020

NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 46
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences